The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. - Wikidata - awgldk - TriplyDB

The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

http://www.wikidata.org/entity/Q46920842

about

Doxorubicin cardiomyopathy The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK/p53 signaling Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.Endothelin B receptor, a new target in cancer immune therapy.Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy.Efficacy and mechanism of angiotensin II receptor blocker treatment in experimental abdominal aortic aneurysms.Potent anti-inflammatory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice Interleukin-6 and tumor necrosis factor-α are associated with quality of life-related symptoms in pulmonary arterial hypertension.Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.Doxorubicin induced heart failure: Phenotype and molecular mechanisms.ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential.Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers.Beyond vasodilator: anti-apoptotic effect of endothelin receptor antagonist.Prevention of Chemotherapy Induced Cardiomyopathy.Signaling Pathways in Cardiac Myocyte Apoptosis.Possible involvement of downregulation of the apelin-APJ system in doxorubicin-induced cardiotoxicity.Anti-Fas gene therapy prevents doxorubicin-induced acute cardiotoxicity through mechanisms independent of apoptosis.Scientific validation of cardioprotective attribute by standardized extract of Bombyx mori against doxorubicin-induced cardiotoxicity in murine model.Cell signaling pathways for the regulation of GATA4 transcription factor: Implications for cell growth and apoptosis.Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice.Carvedilol Attenuates Inflammatory-Mediated Cardiotoxicity in Daunorubicin-Induced Rats.

P2860

Q24606920-EE8D0376-AF8A-47A1-8BF5-115AACA80AA5 Q26823592-0C326958-57F1-4A35-A581-3C5577B0EFB4 Q28543891-5B06F90B-2BE9-420A-81F9-DA00307A5A23 Q30439608-1CEB0715-D5F1-4DC5-94A9-D2ACF7776974 Q33960710-D9277AA7-B73D-41F8-8AE9-C914569FBC7D Q34466688-0073C1A7-3691-43BF-828B-4AA2338D40B5 Q34506416-C173862F-15AB-4DA6-BA2B-307F4EFE933D Q35557932-5F3DF2A9-A75D-47F3-82F7-7D0E34810D01 Q35565086-8A1D6959-50A6-4349-95EF-1D9B06103F88 Q36887091-074D1BCA-BB07-40DB-BC04-7A80BD8FF2E8 Q36912561-6AFDB194-A7F1-4658-9767-E08A156E7092 Q37038890-1696B514-00C0-4FD1-ACA8-AE061CC849BE Q37121891-D8078DFB-13A4-4F50-94CD-66A840D98FBB Q37256842-7941EAB4-02E0-4E43-BE18-43A5D1C03E78 Q38340088-A88E10CF-C955-43FD-800A-B883D611C189 Q38639587-B0759C30-9800-4AF6-92BA-933DB6467B2C Q38768739-FAAA0AE4-F027-42C2-8D36-47F4BDDCF098 Q38909771-53353503-C73A-417A-9364-D1E196C28268 Q42045584-1436BAA7-EBB2-4762-9D19-4C4693143A7E Q42529076-FDE1E82C-A3FF-4258-A7D1-9771D2259F15 Q42718368-5DCF79D2-E850-444A-A94E-538B14F062DB Q46717362-E56B2F1C-A339-4F72-8A34-43EB782FCACD Q46930825-90BB81BC-A5AA-4AC6-837A-9AECD542C3B0

P2860

The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

http://www.wikidata.org/entity/Q46920842

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

@en

The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

@nl

type

label

The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

@en

The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

@nl

prefLabel

The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

@en

The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

@nl

P1433

Q46920842-4CBCE0BB-5FDB-471E-8927-B1CFC4CAE3BC

P1476

Q46920842-8D4C22C6-25DC-435A-96B6-A107A3EC801B

P2093

Q46920842-0DEF91D1-E38B-4B02-A094-0C0F076A1043

Q46920842-45FFD795-05F7-4065-99D7-2E84585CCE04

Q46920842-52E2F1D1-DEB7-4B0E-90D4-C2D5CA2B9596

Q46920842-56E61CC2-56B6-47AB-87AB-B84E444033E3

Q46920842-6AC2B52F-8813-4ED0-A49B-4282871854BA

Q46920842-7EF72006-4A6A-41B2-9ECA-7353C8CAA74D

Q46920842-8B3150AB-9AB2-4D5A-9965-BDC1E399D559

Q46920842-9320B142-3E72-4E11-A5D8-6FDD499B348B

Q46920842-9E9EE808-B22A-430E-BEF6-6DA819B9B45E

Q46920842-A76A7C42-C2D6-4FD6-A96F-1FE17B179B03

P304

Q46920842-EDC7D148-7DF0-43DB-B729-6A2B79A7A4F9

P31

Q46920842-512839C1-E576-4EB2-82F6-2766F23F30DE

P356

Q46920842-19E0E7EF-4B84-4DB7-B71E-F9C14623C2AD

P407

Q46920842-D20B2990-94A8-4DD4-98CC-6E9B1D2E4E72

P433

Q46920842-FBA31836-507B-496E-82A2-2930127EFA57

P478

Q46920842-3BF5E0DE-94E7-4166-B988-A167FBC74C55

P50

Q46920842-95520CE6-2F75-4E13-8FB2-3A791CB7B4B4

Q46920842-C7F29301-2E67-4FBB-8AAC-66E2E5D60F31

P577

Q46920842-32EB69D9-68B6-4BDD-B63C-DAAE243B4447

P5875

Q46920842-08179717-D707-4AF1-B5E8-0033BB982F16

P698

Q46920842-7DA93D3B-6405-4399-89B1-7F5E63869E2C

P356

0008-5472.CAN-07-1344

P1433

Cancer Research

P1476

The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.

@en

P2093

Alexander Riad

http://www.w3.org/2001/XMLSchema#string

Alexander Staudt

http://www.w3.org/2001/XMLSchema#string

Carsten Tschöpe

http://www.w3.org/2001/XMLSchema#string

Christoph A Ritter

http://www.w3.org/2001/XMLSchema#string

Dirk Westermann

http://www.w3.org/2001/XMLSchema#string

Florian Olshausen

http://www.w3.org/2001/XMLSchema#string

Heinz-Peter Schultheiss

http://www.w3.org/2001/XMLSchema#string

Heyo K Kroemer

http://www.w3.org/2001/XMLSchema#string

Markus Grube

http://www.w3.org/2001/XMLSchema#string

Matthias Gratz

http://www.w3.org/2001/XMLSchema#string

P304

10428-10435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-07-1344

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5871383

http://www.w3.org/2001/XMLSchema#string

P698

17974986

http://www.w3.org/2001/XMLSchema#string